nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—GRIN2A—Reelin signaling pathway—NCK2—glaucoma	0.00527	0.0367	CbGpPWpGaD
Acamprosate—SLC36A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC4A4—glaucoma	0.00493	0.0343	CbGpPWpGaD
Acamprosate—GRIN1—Mecp2 and Associated Rett Syndrome—POU4F1—glaucoma	0.00457	0.0318	CbGpPWpGaD
Acamprosate—GRIN2B—Reelin signaling pathway—NCK2—glaucoma	0.00448	0.0312	CbGpPWpGaD
Acamprosate—GRM5—G alpha (q) signalling events—OPN4—glaucoma	0.00346	0.0241	CbGpPWpGaD
Acamprosate—GRM5—G alpha (q) signalling events—PTGFR—glaucoma	0.00312	0.0217	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—OPN4—glaucoma	0.0031	0.0215	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—PTGFR—glaucoma	0.00279	0.0194	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—LMX1B—glaucoma	0.00276	0.0192	CbGpPWpGaD
Acamprosate—SLC36A1—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.0022	0.0153	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—OPN4—glaucoma	0.00175	0.0122	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—NCK2—glaucoma	0.00174	0.0121	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—NCK2—glaucoma	0.0017	0.0118	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—PEX19—glaucoma	0.00166	0.0115	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—PTGFR—glaucoma	0.00157	0.0109	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—LMX1B—glaucoma	0.00156	0.0109	CbGpPWpGaD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.00153	0.0107	CbGpPWpGaD
Acamprosate—SLC36A1—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.00147	0.0102	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—C1QB—glaucoma	0.00143	0.00997	CbGpPWpGaD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.00142	0.00991	CbGpPWpGaD
Acamprosate—GRIN1—Mecp2 and Associated Rett Syndrome—BDNF—glaucoma	0.00136	0.00944	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—NCK2—glaucoma	0.00124	0.00863	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—NCK2—glaucoma	0.00121	0.00841	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—SLC6A13—glaucoma	0.00117	0.00816	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—FAS—glaucoma	0.00117	0.00814	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.00117	0.00813	CbGpPWpGaD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.00112	0.0078	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.00112	0.00779	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—SLC6A13—glaucoma	0.00109	0.00759	CbGpPWpGaD
Acamprosate—GRIN2D—Alzheimers Disease—FAS—glaucoma	0.00109	0.00757	CbGpPWpGaD
Acamprosate—SLC36A1—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.00108	0.00749	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—APOE—glaucoma	0.00107	0.00748	CbGpPWpGaD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.00104	0.00725	CbGpPWpGaD
Acamprosate—GRM5—G alpha (q) signalling events—EDN1—glaucoma	0.00104	0.00721	CbGpPWpGaD
Acamprosate—GRIN1—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.00102	0.0071	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—BAD—glaucoma	0.001	0.00697	CbGpPWpGaD
Acamprosate—GRIN2D—Alzheimers Disease—APOE—glaucoma	0.000999	0.00695	CbGpPWpGaD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.000994	0.00692	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—HDAC9—glaucoma	0.000989	0.00688	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—OPN4—glaucoma	0.000987	0.00687	CbGpPWpGaD
Acamprosate—GRIN2D—Alzheimers Disease—BAD—glaucoma	0.000931	0.00648	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	0.000927	0.00645	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—OPN4—glaucoma	0.000896	0.00624	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—SLC6A13—glaucoma	0.000896	0.00623	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—FAS—glaucoma	0.000894	0.00622	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—PTGFR—glaucoma	0.000889	0.00618	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—SLC6A1—glaucoma	0.000859	0.00598	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.000856	0.00595	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—APOE—glaucoma	0.00082	0.00571	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—NCK2—glaucoma	0.000818	0.00569	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PTGFR—glaucoma	0.000807	0.00561	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—SLC6A1—glaucoma	0.000798	0.00556	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—SMO—glaucoma	0.000793	0.00552	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—SLC6A13—glaucoma	0.000781	0.00544	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—FAS—glaucoma	0.000779	0.00542	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—BAD—glaucoma	0.000764	0.00532	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—LRP12—glaucoma	0.000764	0.00531	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—SLC6A13—glaucoma	0.000762	0.0053	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—FAS—glaucoma	0.00076	0.00529	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—NGFR—glaucoma	0.00076	0.00528	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—NTRK2—glaucoma	0.000755	0.00525	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000747	0.0052	CbGpPWpGaD
Acamprosate—GRIN1—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.000746	0.00519	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—NTRK2—glaucoma	0.000736	0.00512	CbGpPWpGaD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.000728	0.00506	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—APOE—glaucoma	0.000715	0.00498	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—NTRK2—glaucoma	0.000708	0.00493	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—APOE—glaucoma	0.000697	0.00485	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.000673	0.00468	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—BAD—glaucoma	0.000667	0.00464	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—BDNF—glaucoma	0.000661	0.0046	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.000661	0.0046	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—SLC6A1—glaucoma	0.000656	0.00456	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—BAD—glaucoma	0.00065	0.00452	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—NCK2—glaucoma	0.000648	0.00451	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—NGFR—glaucoma	0.000648	0.00451	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—IL1A—glaucoma	0.000634	0.00441	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—NCK2—glaucoma	0.000632	0.0044	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—NGFR—glaucoma	0.000631	0.00439	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—NTRK1—glaucoma	0.000615	0.00428	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—PEX19—glaucoma	0.000615	0.00428	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—PEX19—glaucoma	0.000604	0.0042	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—NTRK1—glaucoma	0.0006	0.00417	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.000577	0.00402	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—SLC6A1—glaucoma	0.000572	0.00398	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—BDNF—glaucoma	0.000563	0.00392	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—HDAC9—glaucoma	0.00056	0.0039	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—SLC6A1—glaucoma	0.000557	0.00388	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—BDNF—glaucoma	0.000549	0.00382	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000547	0.00381	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—OPN4—glaucoma	0.000529	0.00368	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—BDNF—glaucoma	0.000528	0.00368	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—PEX19—glaucoma	0.000528	0.00367	CbGpPWpGaD
Acamprosate—Asthenia—Bimatoprost—glaucoma	0.000523	0.000611	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—EDN1—glaucoma	0.000523	0.00364	CbGpPWpGaD
Acamprosate—Angioedema—Clonidine—glaucoma	0.000521	0.000608	CcSEcCtD
Acamprosate—Dyspnoea—Pilocarpine—glaucoma	0.00052	0.000607	CcSEcCtD
Acamprosate—Pain—Brinzolamide—glaucoma	0.000518	0.000605	CcSEcCtD
Acamprosate—Somnolence—Pilocarpine—glaucoma	0.000518	0.000605	CcSEcCtD
Acamprosate—Depression—Timolol—glaucoma	0.000517	0.000604	CcSEcCtD
Acamprosate—Pruritus—Bimatoprost—glaucoma	0.000516	0.000603	CcSEcCtD
Acamprosate—GABRB3—Neuronal System—SLC6A13—glaucoma	0.000515	0.00359	CbGpPWpGaD
Acamprosate—Immune system disorder—Betaxolol—glaucoma	0.000515	0.000602	CcSEcCtD
Acamprosate—Diarrhoea—Apraclonidine—glaucoma	0.000515	0.000601	CcSEcCtD
Acamprosate—Malaise—Clonidine—glaucoma	0.000514	0.000601	CcSEcCtD
Acamprosate—Dyspepsia—Pilocarpine—glaucoma	0.000513	0.000599	CcSEcCtD
Acamprosate—Chills—Betaxolol—glaucoma	0.000512	0.000598	CcSEcCtD
Acamprosate—Syncope—Clonidine—glaucoma	0.000511	0.000597	CcSEcCtD
Acamprosate—Feeling abnormal—Dorzolamide—glaucoma	0.000508	0.000594	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—IL1A—glaucoma	0.000507	0.00353	CbGpPWpGaD
Acamprosate—Decreased appetite—Pilocarpine—glaucoma	0.000507	0.000592	CcSEcCtD
Acamprosate—GABRG2—Neuronal System—SLC6A13—glaucoma	0.000506	0.00352	CbGpPWpGaD
Acamprosate—Feeling abnormal—Travoprost—glaucoma	0.000506	0.000591	CcSEcCtD
Acamprosate—Gastrointestinal pain—Dorzolamide—glaucoma	0.000504	0.000589	CcSEcCtD
Acamprosate—Alopecia—Betaxolol—glaucoma	0.000504	0.000589	CcSEcCtD
Acamprosate—Palpitations—Clonidine—glaucoma	0.000504	0.000588	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000503	0.000588	CcSEcCtD
Acamprosate—Gastrointestinal pain—Travoprost—glaucoma	0.000502	0.000586	CcSEcCtD
Acamprosate—Loss of consciousness—Clonidine—glaucoma	0.000501	0.000585	CcSEcCtD
Acamprosate—GRIN1—BDNF signaling pathway—NGF—glaucoma	0.0005	0.00348	CbGpPWpGaD
Acamprosate—Feeling abnormal—Brinzolamide—glaucoma	0.0005	0.000583	CcSEcCtD
Acamprosate—Mental disorder—Betaxolol—glaucoma	0.0005	0.000583	CcSEcCtD
Acamprosate—Pain—Pilocarpine—glaucoma	0.000498	0.000582	CcSEcCtD
Acamprosate—Constipation—Pilocarpine—glaucoma	0.000498	0.000582	CcSEcCtD
Acamprosate—GABRB3—BDNF signaling pathway—NTRK2—glaucoma	0.000498	0.00347	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—MMP2—glaucoma	0.000498	0.00346	CbGpPWpGaD
Acamprosate—Cough—Clonidine—glaucoma	0.000498	0.000581	CcSEcCtD
Acamprosate—Sweating—Timolol—glaucoma	0.000498	0.000581	CcSEcCtD
Acamprosate—Dizziness—Apraclonidine—glaucoma	0.000497	0.000581	CcSEcCtD
Acamprosate—GRIN2C—Alzheimers Disease—TNF—glaucoma	0.000497	0.00346	CbGpPWpGaD
Acamprosate—Malnutrition—Betaxolol—glaucoma	0.000496	0.00058	CcSEcCtD
Acamprosate—GABRB3—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.000492	0.00343	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—HEYL—glaucoma	0.000492	0.00342	CbGpPWpGaD
Acamprosate—Urticaria—Dorzolamide—glaucoma	0.00049	0.000572	CcSEcCtD
Acamprosate—Epistaxis—Timolol—glaucoma	0.000489	0.000572	CcSEcCtD
Acamprosate—Abdominal pain—Dorzolamide—glaucoma	0.000488	0.000569	CcSEcCtD
Acamprosate—Body temperature increased—Dorzolamide—glaucoma	0.000488	0.000569	CcSEcCtD
Acamprosate—GRIN2B—BDNF signaling pathway—NGF—glaucoma	0.000487	0.00339	CbGpPWpGaD
Acamprosate—Tension—Betaxolol—glaucoma	0.000487	0.000569	CcSEcCtD
Acamprosate—Dysgeusia—Betaxolol—glaucoma	0.000486	0.000568	CcSEcCtD
Acamprosate—Chest pain—Clonidine—glaucoma	0.000485	0.000567	CcSEcCtD
Acamprosate—Arthralgia—Clonidine—glaucoma	0.000485	0.000567	CcSEcCtD
Acamprosate—Abdominal pain—Travoprost—glaucoma	0.000485	0.000567	CcSEcCtD
Acamprosate—GRIN2B—EPH-Ephrin signaling—MMP2—glaucoma	0.000485	0.00338	CbGpPWpGaD
Acamprosate—Anxiety—Clonidine—glaucoma	0.000484	0.000565	CcSEcCtD
Acamprosate—GABRG2—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.000484	0.00336	CbGpPWpGaD
Acamprosate—Asthenia—Acetazolamide—glaucoma	0.000483	0.000564	CcSEcCtD
Acamprosate—Dizziness—Bimatoprost—glaucoma	0.000482	0.000563	CcSEcCtD
Acamprosate—Nervousness—Betaxolol—glaucoma	0.000482	0.000563	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000482	0.000563	CcSEcCtD
Acamprosate—Urticaria—Brinzolamide—glaucoma	0.000482	0.000562	CcSEcCtD
Acamprosate—Feeling abnormal—Pilocarpine—glaucoma	0.00048	0.000561	CcSEcCtD
Acamprosate—Discomfort—Clonidine—glaucoma	0.00048	0.00056	CcSEcCtD
Acamprosate—Vomiting—Apraclonidine—glaucoma	0.000478	0.000559	CcSEcCtD
Acamprosate—Muscle spasms—Betaxolol—glaucoma	0.000477	0.000557	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—PTGFR—glaucoma	0.000477	0.00332	CbGpPWpGaD
Acamprosate—Gastrointestinal pain—Pilocarpine—glaucoma	0.000477	0.000556	CcSEcCtD
Acamprosate—Hypersensitivity—Brimonidine—glaucoma	0.000476	0.000556	CcSEcCtD
Acamprosate—Dry mouth—Clonidine—glaucoma	0.000475	0.000554	CcSEcCtD
Acamprosate—Dermatitis—Apraclonidine—glaucoma	0.000474	0.000553	CcSEcCtD
Acamprosate—Headache—Apraclonidine—glaucoma	0.000471	0.00055	CcSEcCtD
Acamprosate—Confusional state—Clonidine—glaucoma	0.000469	0.000548	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—NGF—glaucoma	0.000469	0.00326	CbGpPWpGaD
Acamprosate—Rhinitis—Timolol—glaucoma	0.000467	0.000545	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—NR3C1—glaucoma	0.000467	0.00325	CbGpPWpGaD
Acamprosate—Tremor—Betaxolol—glaucoma	0.000465	0.000543	CcSEcCtD
Acamprosate—Hallucination—Timolol—glaucoma	0.000464	0.000541	CcSEcCtD
Acamprosate—Asthenia—Brimonidine—glaucoma	0.000463	0.000541	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—NCK2—glaucoma	0.000463	0.00322	CbGpPWpGaD
Acamprosate—Infection—Clonidine—glaucoma	0.000462	0.00054	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—TNF—glaucoma	0.000462	0.00321	CbGpPWpGaD
Acamprosate—Abdominal pain—Pilocarpine—glaucoma	0.000461	0.000538	CcSEcCtD
Acamprosate—Body temperature increased—Pilocarpine—glaucoma	0.000461	0.000538	CcSEcCtD
Acamprosate—Ill-defined disorder—Betaxolol—glaucoma	0.000461	0.000538	CcSEcCtD
Acamprosate—Diarrhoea—Acetazolamide—glaucoma	0.00046	0.000538	CcSEcCtD
Acamprosate—Rash—Bimatoprost—glaucoma	0.00046	0.000537	CcSEcCtD
Acamprosate—Dermatitis—Bimatoprost—glaucoma	0.000459	0.000537	CcSEcCtD
Acamprosate—Oedema peripheral—Timolol—glaucoma	0.000459	0.000536	CcSEcCtD
Acamprosate—Anaemia—Betaxolol—glaucoma	0.000459	0.000536	CcSEcCtD
Acamprosate—Shock—Clonidine—glaucoma	0.000458	0.000535	CcSEcCtD
Acamprosate—Pruritus—Brimonidine—glaucoma	0.000457	0.000534	CcSEcCtD
Acamprosate—Headache—Bimatoprost—glaucoma	0.000457	0.000534	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—C3—glaucoma	0.000457	0.00318	CbGpPWpGaD
Acamprosate—Thrombocytopenia—Clonidine—glaucoma	0.000456	0.000532	CcSEcCtD
Acamprosate—Hypersensitivity—Dorzolamide—glaucoma	0.000454	0.000531	CcSEcCtD
Acamprosate—Tachycardia—Clonidine—glaucoma	0.000454	0.00053	CcSEcCtD
Acamprosate—Hypersensitivity—Travoprost—glaucoma	0.000452	0.000528	CcSEcCtD
Acamprosate—Skin disorder—Clonidine—glaucoma	0.000452	0.000528	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—NCK2—glaucoma	0.000451	0.00314	CbGpPWpGaD
Acamprosate—Hyperhidrosis—Clonidine—glaucoma	0.00045	0.000525	CcSEcCtD
Acamprosate—Visual impairment—Timolol—glaucoma	0.000449	0.000524	CcSEcCtD
Acamprosate—Malaise—Betaxolol—glaucoma	0.000448	0.000523	CcSEcCtD
Acamprosate—Nausea—Apraclonidine—glaucoma	0.000447	0.000522	CcSEcCtD
Acamprosate—Hypersensitivity—Brinzolamide—glaucoma	0.000447	0.000522	CcSEcCtD
Acamprosate—Vertigo—Betaxolol—glaucoma	0.000446	0.000521	CcSEcCtD
Acamprosate—Syncope—Betaxolol—glaucoma	0.000445	0.00052	CcSEcCtD
Acamprosate—Dizziness—Acetazolamide—glaucoma	0.000445	0.00052	CcSEcCtD
Acamprosate—Anorexia—Clonidine—glaucoma	0.000444	0.000518	CcSEcCtD
Acamprosate—Asthenia—Dorzolamide—glaucoma	0.000442	0.000517	CcSEcCtD
Acamprosate—GABRA1—Neuronal System—SLC6A13—glaucoma	0.000442	0.00308	CbGpPWpGaD
Acamprosate—Asthenia—Travoprost—glaucoma	0.000441	0.000515	CcSEcCtD
Acamprosate—Palpitations—Betaxolol—glaucoma	0.000439	0.000512	CcSEcCtD
Acamprosate—GRIN2C—Alzheimers Disease—TP53—glaucoma	0.000438	0.00305	CbGpPWpGaD
Acamprosate—Pruritus—Dorzolamide—glaucoma	0.000436	0.00051	CcSEcCtD
Acamprosate—Loss of consciousness—Betaxolol—glaucoma	0.000436	0.00051	CcSEcCtD
Acamprosate—Asthenia—Brinzolamide—glaucoma	0.000435	0.000508	CcSEcCtD
Acamprosate—Hypotension—Clonidine—glaucoma	0.000435	0.000508	CcSEcCtD
Acamprosate—Pruritus—Travoprost—glaucoma	0.000434	0.000507	CcSEcCtD
Acamprosate—Tinnitus—Timolol—glaucoma	0.000434	0.000507	CcSEcCtD
Acamprosate—Cough—Betaxolol—glaucoma	0.000433	0.000506	CcSEcCtD
Acamprosate—Nausea—Bimatoprost—glaucoma	0.000433	0.000506	CcSEcCtD
Acamprosate—Hypersensitivity—Pilocarpine—glaucoma	0.000429	0.000501	CcSEcCtD
Acamprosate—Pruritus—Brinzolamide—glaucoma	0.000429	0.000501	CcSEcCtD
Acamprosate—Vomiting—Acetazolamide—glaucoma	0.000428	0.0005	CcSEcCtD
Acamprosate—GABRB3—BDNF signaling pathway—NGFR—glaucoma	0.000427	0.00297	CbGpPWpGaD
Acamprosate—Dizziness—Brimonidine—glaucoma	0.000427	0.000499	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Clonidine—glaucoma	0.000424	0.000495	CcSEcCtD
Acamprosate—Myalgia—Betaxolol—glaucoma	0.000423	0.000494	CcSEcCtD
Acamprosate—Arthralgia—Betaxolol—glaucoma	0.000423	0.000494	CcSEcCtD
Acamprosate—Chest pain—Betaxolol—glaucoma	0.000423	0.000494	CcSEcCtD
Acamprosate—GABRA1—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.000423	0.00294	CbGpPWpGaD
Acamprosate—Diarrhoea—Dorzolamide—glaucoma	0.000422	0.000493	CcSEcCtD
Acamprosate—Headache—Acetazolamide—glaucoma	0.000422	0.000492	CcSEcCtD
Acamprosate—Anxiety—Betaxolol—glaucoma	0.000421	0.000492	CcSEcCtD
Acamprosate—Insomnia—Clonidine—glaucoma	0.000421	0.000492	CcSEcCtD
Acamprosate—Immune system disorder—Timolol—glaucoma	0.000421	0.000491	CcSEcCtD
Acamprosate—Diarrhoea—Travoprost—glaucoma	0.00042	0.000491	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.00042	0.00049	CcSEcCtD
Acamprosate—Asthenia—Pilocarpine—glaucoma	0.000418	0.000488	CcSEcCtD
Acamprosate—Paraesthesia—Clonidine—glaucoma	0.000418	0.000488	CcSEcCtD
Acamprosate—Discomfort—Betaxolol—glaucoma	0.000418	0.000488	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000415	0.00289	CbGpPWpGaD
Acamprosate—Dyspnoea—Clonidine—glaucoma	0.000415	0.000485	CcSEcCtD
Acamprosate—Diarrhoea—Brinzolamide—glaucoma	0.000415	0.000484	CcSEcCtD
Acamprosate—Somnolence—Clonidine—glaucoma	0.000414	0.000483	CcSEcCtD
Acamprosate—Dry mouth—Betaxolol—glaucoma	0.000413	0.000483	CcSEcCtD
Acamprosate—GRIN1—BDNF signaling pathway—BAD—glaucoma	0.000412	0.00287	CbGpPWpGaD
Acamprosate—Pruritus—Pilocarpine—glaucoma	0.000412	0.000481	CcSEcCtD
Acamprosate—Alopecia—Timolol—glaucoma	0.000412	0.000481	CcSEcCtD
Acamprosate—Confusional state—Betaxolol—glaucoma	0.000409	0.000477	CcSEcCtD
Acamprosate—Mental disorder—Timolol—glaucoma	0.000408	0.000477	CcSEcCtD
Acamprosate—GABRG2—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000408	0.00284	CbGpPWpGaD
Acamprosate—Dizziness—Dorzolamide—glaucoma	0.000408	0.000476	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—TP53—glaucoma	0.000407	0.00283	CbGpPWpGaD
Acamprosate—Rash—Brimonidine—glaucoma	0.000407	0.000476	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—SMO—glaucoma	0.000407	0.00283	CbGpPWpGaD
Acamprosate—Dermatitis—Brimonidine—glaucoma	0.000407	0.000475	CcSEcCtD
Acamprosate—Dizziness—Travoprost—glaucoma	0.000406	0.000474	CcSEcCtD
Acamprosate—GABRB3—BDNF signaling pathway—NTRK1—glaucoma	0.000406	0.00282	CbGpPWpGaD
Acamprosate—Malnutrition—Timolol—glaucoma	0.000406	0.000474	CcSEcCtD
Acamprosate—Headache—Brimonidine—glaucoma	0.000405	0.000472	CcSEcCtD
Acamprosate—Decreased appetite—Clonidine—glaucoma	0.000405	0.000472	CcSEcCtD
Acamprosate—Infection—Betaxolol—glaucoma	0.000403	0.00047	CcSEcCtD
Acamprosate—GRIN2B—BDNF signaling pathway—BAD—glaucoma	0.000402	0.0028	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Clonidine—glaucoma	0.000402	0.000469	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—NTRK2—glaucoma	0.000401	0.00279	CbGpPWpGaD
Acamprosate—Dizziness—Brinzolamide—glaucoma	0.000401	0.000468	CcSEcCtD
Acamprosate—Nausea—Acetazolamide—glaucoma	0.0004	0.000467	CcSEcCtD
Acamprosate—Diarrhoea—Pilocarpine—glaucoma	0.000399	0.000466	CcSEcCtD
Acamprosate—Shock—Betaxolol—glaucoma	0.000399	0.000466	CcSEcCtD
Acamprosate—Tension—Timolol—glaucoma	0.000398	0.000465	CcSEcCtD
Acamprosate—Pain—Clonidine—glaucoma	0.000398	0.000465	CcSEcCtD
Acamprosate—Constipation—Clonidine—glaucoma	0.000398	0.000465	CcSEcCtD
Acamprosate—Dysgeusia—Timolol—glaucoma	0.000397	0.000464	CcSEcCtD
Acamprosate—Thrombocytopenia—Betaxolol—glaucoma	0.000397	0.000463	CcSEcCtD
Acamprosate—Tachycardia—Betaxolol—glaucoma	0.000395	0.000462	CcSEcCtD
Acamprosate—Nervousness—Timolol—glaucoma	0.000394	0.00046	CcSEcCtD
Acamprosate—Skin disorder—Betaxolol—glaucoma	0.000394	0.00046	CcSEcCtD
Acamprosate—Vomiting—Dorzolamide—glaucoma	0.000392	0.000458	CcSEcCtD
Acamprosate—Hyperhidrosis—Betaxolol—glaucoma	0.000392	0.000457	CcSEcCtD
Acamprosate—Rash—Dorzolamide—glaucoma	0.000389	0.000454	CcSEcCtD
Acamprosate—Dermatitis—Dorzolamide—glaucoma	0.000388	0.000454	CcSEcCtD
Acamprosate—Rash—Travoprost—glaucoma	0.000387	0.000452	CcSEcCtD
Acamprosate—Dermatitis—Travoprost—glaucoma	0.000387	0.000452	CcSEcCtD
Acamprosate—Headache—Dorzolamide—glaucoma	0.000386	0.000451	CcSEcCtD
Acamprosate—Anorexia—Betaxolol—glaucoma	0.000386	0.000451	CcSEcCtD
Acamprosate—Vomiting—Brinzolamide—glaucoma	0.000385	0.00045	CcSEcCtD
Acamprosate—Dizziness—Pilocarpine—glaucoma	0.000385	0.00045	CcSEcCtD
Acamprosate—Headache—Travoprost—glaucoma	0.000385	0.000449	CcSEcCtD
Acamprosate—Nausea—Brimonidine—glaucoma	0.000384	0.000448	CcSEcCtD
Acamprosate—Feeling abnormal—Clonidine—glaucoma	0.000383	0.000448	CcSEcCtD
Acamprosate—Rash—Brinzolamide—glaucoma	0.000382	0.000446	CcSEcCtD
Acamprosate—Dermatitis—Brinzolamide—glaucoma	0.000382	0.000446	CcSEcCtD
Acamprosate—Gastrointestinal pain—Clonidine—glaucoma	0.000381	0.000444	CcSEcCtD
Acamprosate—Headache—Brinzolamide—glaucoma	0.00038	0.000444	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—TNF—glaucoma	0.000379	0.00264	CbGpPWpGaD
Acamprosate—Hypotension—Betaxolol—glaucoma	0.000379	0.000442	CcSEcCtD
Acamprosate—GABRB3—Neuronal System—SLC6A1—glaucoma	0.000377	0.00263	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—MMP9—glaucoma	0.000374	0.0026	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—RPTOR—glaucoma	0.000373	0.0026	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—BDNF—glaucoma	0.000372	0.00259	CbGpPWpGaD
Acamprosate—Angioedema—Timolol—glaucoma	0.000371	0.000433	CcSEcCtD
Acamprosate—Vomiting—Pilocarpine—glaucoma	0.000371	0.000433	CcSEcCtD
Acamprosate—GABRG2—Neuronal System—SLC6A1—glaucoma	0.00037	0.00258	CbGpPWpGaD
Acamprosate—Urticaria—Clonidine—glaucoma	0.00037	0.000432	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000369	0.000431	CcSEcCtD
Acamprosate—Body temperature increased—Clonidine—glaucoma	0.000368	0.00043	CcSEcCtD
Acamprosate—Abdominal pain—Clonidine—glaucoma	0.000368	0.00043	CcSEcCtD
Acamprosate—Rash—Pilocarpine—glaucoma	0.000367	0.000429	CcSEcCtD
Acamprosate—Dermatitis—Pilocarpine—glaucoma	0.000367	0.000429	CcSEcCtD
Acamprosate—Insomnia—Betaxolol—glaucoma	0.000366	0.000428	CcSEcCtD
Acamprosate—Nausea—Dorzolamide—glaucoma	0.000366	0.000428	CcSEcCtD
Acamprosate—Headache—Pilocarpine—glaucoma	0.000365	0.000426	CcSEcCtD
Acamprosate—GRIN2B—EPH-Ephrin signaling—MMP9—glaucoma	0.000365	0.00254	CbGpPWpGaD
Acamprosate—Nausea—Travoprost—glaucoma	0.000365	0.000426	CcSEcCtD
Acamprosate—Vertigo—Timolol—glaucoma	0.000364	0.000426	CcSEcCtD
Acamprosate—Paraesthesia—Betaxolol—glaucoma	0.000364	0.000425	CcSEcCtD
Acamprosate—Syncope—Timolol—glaucoma	0.000364	0.000425	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—NCK2—glaucoma	0.000361	0.00251	CbGpPWpGaD
Acamprosate—Dyspnoea—Betaxolol—glaucoma	0.000361	0.000422	CcSEcCtD
Acamprosate—Nausea—Brinzolamide—glaucoma	0.00036	0.000421	CcSEcCtD
Acamprosate—Palpitations—Timolol—glaucoma	0.000358	0.000419	CcSEcCtD
Acamprosate—Dyspepsia—Betaxolol—glaucoma	0.000357	0.000416	CcSEcCtD
Acamprosate—GABRA1—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000357	0.00248	CbGpPWpGaD
Acamprosate—Loss of consciousness—Timolol—glaucoma	0.000356	0.000416	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—PTGS2—glaucoma	0.000356	0.00247	CbGpPWpGaD
Acamprosate—Cough—Timolol—glaucoma	0.000354	0.000413	CcSEcCtD
Acamprosate—Decreased appetite—Betaxolol—glaucoma	0.000352	0.000411	CcSEcCtD
Acamprosate—Hypertension—Timolol—glaucoma	0.00035	0.000409	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Betaxolol—glaucoma	0.00035	0.000408	CcSEcCtD
Acamprosate—Pain—Betaxolol—glaucoma	0.000346	0.000405	CcSEcCtD
Acamprosate—Constipation—Betaxolol—glaucoma	0.000346	0.000405	CcSEcCtD
Acamprosate—Nausea—Pilocarpine—glaucoma	0.000346	0.000404	CcSEcCtD
Acamprosate—Arthralgia—Timolol—glaucoma	0.000345	0.000403	CcSEcCtD
Acamprosate—Myalgia—Timolol—glaucoma	0.000345	0.000403	CcSEcCtD
Acamprosate—Chest pain—Timolol—glaucoma	0.000345	0.000403	CcSEcCtD
Acamprosate—Anxiety—Timolol—glaucoma	0.000344	0.000402	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000343	0.0004	CcSEcCtD
Acamprosate—Hypersensitivity—Clonidine—glaucoma	0.000343	0.0004	CcSEcCtD
Acamprosate—Discomfort—Timolol—glaucoma	0.000341	0.000398	CcSEcCtD
Acamprosate—Dry mouth—Timolol—glaucoma	0.000338	0.000394	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—CDKN1B—glaucoma	0.000337	0.00234	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—VEGFA—glaucoma	0.000336	0.00234	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—TP53—glaucoma	0.000335	0.00233	CbGpPWpGaD
Acamprosate—Asthenia—Clonidine—glaucoma	0.000334	0.00039	CcSEcCtD
Acamprosate—Feeling abnormal—Betaxolol—glaucoma	0.000334	0.00039	CcSEcCtD
Acamprosate—Confusional state—Timolol—glaucoma	0.000334	0.00039	CcSEcCtD
Acamprosate—Anaphylactic shock—Timolol—glaucoma	0.000331	0.000387	CcSEcCtD
Acamprosate—GRIN1—Alzheimers Disease—TNF—glaucoma	0.000331	0.0023	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—NGF—glaucoma	0.00033	0.0023	CbGpPWpGaD
Acamprosate—Pruritus—Clonidine—glaucoma	0.000329	0.000385	CcSEcCtD
Acamprosate—Infection—Timolol—glaucoma	0.000329	0.000384	CcSEcCtD
Acamprosate—GRIN2B—EPH-Ephrin signaling—VEGFA—glaucoma	0.000328	0.00228	CbGpPWpGaD
Acamprosate—Shock—Timolol—glaucoma	0.000326	0.00038	CcSEcCtD
Acamprosate—GABRA1—Neuronal System—SLC6A1—glaucoma	0.000324	0.00225	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—TNF—glaucoma	0.000323	0.00224	CbGpPWpGaD
Acamprosate—Urticaria—Betaxolol—glaucoma	0.000322	0.000376	CcSEcCtD
Acamprosate—Skin disorder—Timolol—glaucoma	0.000321	0.000375	CcSEcCtD
Acamprosate—Body temperature increased—Betaxolol—glaucoma	0.00032	0.000374	CcSEcCtD
Acamprosate—Hyperhidrosis—Timolol—glaucoma	0.00032	0.000374	CcSEcCtD
Acamprosate—Diarrhoea—Clonidine—glaucoma	0.000318	0.000372	CcSEcCtD
Acamprosate—Anorexia—Timolol—glaucoma	0.000315	0.000368	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—MMP9—glaucoma	0.000312	0.00217	CbGpPWpGaD
Acamprosate—Hypotension—Timolol—glaucoma	0.000309	0.000361	CcSEcCtD
Acamprosate—Dizziness—Clonidine—glaucoma	0.000308	0.000359	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—HDAC9—glaucoma	0.000307	0.00214	CbGpPWpGaD
Acamprosate—Musculoskeletal discomfort—Timolol—glaucoma	0.000302	0.000352	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—PAX6—glaucoma	0.0003	0.00209	CbGpPWpGaD
Acamprosate—Insomnia—Timolol—glaucoma	0.000299	0.00035	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—BDNF—glaucoma	0.000299	0.00208	CbGpPWpGaD
Acamprosate—Hypersensitivity—Betaxolol—glaucoma	0.000298	0.000349	CcSEcCtD
Acamprosate—Paraesthesia—Timolol—glaucoma	0.000297	0.000347	CcSEcCtD
Acamprosate—Vomiting—Clonidine—glaucoma	0.000296	0.000346	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—EDN1—glaucoma	0.000295	0.00206	CbGpPWpGaD
Acamprosate—Dyspnoea—Timolol—glaucoma	0.000295	0.000345	CcSEcCtD
Acamprosate—Somnolence—Timolol—glaucoma	0.000294	0.000344	CcSEcCtD
Acamprosate—Rash—Clonidine—glaucoma	0.000293	0.000343	CcSEcCtD
Acamprosate—Dermatitis—Clonidine—glaucoma	0.000293	0.000342	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—PAX6—glaucoma	0.000292	0.00203	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—TP53—glaucoma	0.000292	0.00203	CbGpPWpGaD
Acamprosate—Headache—Clonidine—glaucoma	0.000292	0.00034	CcSEcCtD
Acamprosate—Dyspepsia—Timolol—glaucoma	0.000291	0.00034	CcSEcCtD
Acamprosate—Asthenia—Betaxolol—glaucoma	0.000291	0.000339	CcSEcCtD
Acamprosate—Decreased appetite—Timolol—glaucoma	0.000288	0.000336	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—IL1A—glaucoma	0.000287	0.002	CbGpPWpGaD
Acamprosate—Pruritus—Betaxolol—glaucoma	0.000287	0.000335	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Timolol—glaucoma	0.000286	0.000334	CcSEcCtD
Acamprosate—GRIN2B—Alzheimers Disease—TP53—glaucoma	0.000284	0.00198	CbGpPWpGaD
Acamprosate—Pain—Timolol—glaucoma	0.000283	0.000331	CcSEcCtD
Acamprosate—Diarrhoea—Betaxolol—glaucoma	0.000277	0.000324	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000277	0.00193	CbGpPWpGaD
Acamprosate—Nausea—Clonidine—glaucoma	0.000276	0.000323	CcSEcCtD
Acamprosate—Feeling abnormal—Timolol—glaucoma	0.000273	0.000319	CcSEcCtD
Acamprosate—GABRG2—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000272	0.00189	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—BAD—glaucoma	0.000272	0.00189	CbGpPWpGaD
Acamprosate—Gastrointestinal pain—Timolol—glaucoma	0.000271	0.000316	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—EDN1—glaucoma	0.000268	0.00187	CbGpPWpGaD
Acamprosate—Dizziness—Betaxolol—glaucoma	0.000268	0.000313	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—NGF—glaucoma	0.000266	0.00185	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—NR3C1—glaucoma	0.000264	0.00184	CbGpPWpGaD
Acamprosate—Urticaria—Timolol—glaucoma	0.000263	0.000307	CcSEcCtD
Acamprosate—Body temperature increased—Timolol—glaucoma	0.000262	0.000306	CcSEcCtD
Acamprosate—Abdominal pain—Timolol—glaucoma	0.000262	0.000306	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—C3—glaucoma	0.000258	0.0018	CbGpPWpGaD
Acamprosate—Vomiting—Betaxolol—glaucoma	0.000258	0.000301	CcSEcCtD
Acamprosate—Rash—Betaxolol—glaucoma	0.000255	0.000298	CcSEcCtD
Acamprosate—Dermatitis—Betaxolol—glaucoma	0.000255	0.000298	CcSEcCtD
Acamprosate—Headache—Betaxolol—glaucoma	0.000254	0.000296	CcSEcCtD
Acamprosate—Hypersensitivity—Timolol—glaucoma	0.000244	0.000285	CcSEcCtD
Acamprosate—Nausea—Betaxolol—glaucoma	0.000241	0.000281	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—SMO—glaucoma	0.00024	0.00167	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TNF—glaucoma	0.00024	0.00167	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000238	0.00166	CbGpPWpGaD
Acamprosate—Asthenia—Timolol—glaucoma	0.000237	0.000277	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—C3—glaucoma	0.000234	0.00163	CbGpPWpGaD
Acamprosate—Pruritus—Timolol—glaucoma	0.000234	0.000273	CcSEcCtD
Acamprosate—Diarrhoea—Timolol—glaucoma	0.000226	0.000264	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—VEGFA—glaucoma	0.000224	0.00156	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NTRK2—glaucoma	0.00022	0.00153	CbGpPWpGaD
Acamprosate—Dizziness—Timolol—glaucoma	0.000219	0.000256	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—TP53—glaucoma	0.000212	0.00147	CbGpPWpGaD
Acamprosate—Vomiting—Timolol—glaucoma	0.00021	0.000246	CcSEcCtD
Acamprosate—Rash—Timolol—glaucoma	0.000209	0.000244	CcSEcCtD
Acamprosate—Dermatitis—Timolol—glaucoma	0.000208	0.000243	CcSEcCtD
Acamprosate—Headache—Timolol—glaucoma	0.000207	0.000242	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000203	0.00141	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000199	0.00139	CbGpPWpGaD
Acamprosate—Nausea—Timolol—glaucoma	0.000197	0.00023	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—TNF—glaucoma	0.000192	0.00134	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NGFR—glaucoma	0.000189	0.00131	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—MMP2—glaucoma	0.000185	0.00129	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—MMP2—glaucoma	0.00018	0.00125	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NTRK1—glaucoma	0.000179	0.00125	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000174	0.00121	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CDKN2B—glaucoma	0.000165	0.00115	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—EDN1—glaucoma	0.000158	0.0011	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NGF—glaucoma	0.000146	0.00101	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—MMP9—glaucoma	0.000139	0.000967	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—C3—glaucoma	0.000138	0.000963	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—MMP9—glaucoma	0.000136	0.000943	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—MMP2—glaucoma	0.000132	0.000919	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—APOE—glaucoma	0.000129	0.000897	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MMP2—glaucoma	0.000129	0.000895	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CAV1—glaucoma	0.000128	0.000889	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—VEGFA—glaucoma	0.000127	0.000883	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—VEGFA—glaucoma	0.000125	0.000869	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—VEGFA—glaucoma	0.000122	0.000847	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—FN1—glaucoma	0.000122	0.000846	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—BAD—glaucoma	0.00012	0.000836	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—TNF—glaucoma	0.000109	0.000757	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—MMP9—glaucoma	9.92e-05	0.00069	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MMP9—glaucoma	9.67e-05	0.000673	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NOS3—glaucoma	9.66e-05	0.000672	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—VEGFA—glaucoma	8.91e-05	0.00062	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—VEGFA—glaucoma	8.69e-05	0.000604	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CDKN1B—glaucoma	8.36e-05	0.000582	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MMP9—glaucoma	7.75e-05	0.000539	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—TNF—glaucoma	7.64e-05	0.000531	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—TNF—glaucoma	7.44e-05	0.000518	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—VEGFA—glaucoma	6.96e-05	0.000484	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TP53—glaucoma	5.26e-05	0.000366	CbGpPWpGaD
